Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 5, 2009, Pages 529-538

  White, Harvey D ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Acute coronary syndromes; Antithrombins; Bivalirudin; Direct thrombin inhibitors

Indexed keywords

ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ACUTE CORONARY SYNDROME; ANEMIA; ANGIOPLASTY; BLEEDING; BLOOD TRANSFUSION; CONGESTIVE HEART FAILURE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; HYPOTENSION; HYPOVOLEMIA; ISCHEMIA; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRACTICE GUIDELINE; PROTHROMBIN TIME; REVIEW; ST SEGMENT ELEVATION; STENT THROMBOSIS; TACHYCARDIA; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; THROMBIN;

EID: 67649396056     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902845646     Document Type: Review

References (46)

1. World Health Organisation. Cardiovascular diseases. Available from: http://www.who. int/mediacentre/factsheets/fs317/en/index. html. 2008. 13-8-2008
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326:242-250
3. Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circ 2007;116:305-315 (Pubitemid 47196567)
4. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106 (Pubitemid 24052591)
5. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-1942 (Pubitemid 30326097)
6. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673-682 (Pubitemid 23252260)
7. Mehta S, Eikelboom JW, Yusuf S. Long-term management of unstable angina and non-Q-wave myocardial infarction. Eur Heart J 2008;2:E6-12
8. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S (Pubitemid 28535777)
9. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004;30:273-283 (Pubitemid 39037620)
10. Mureebe L, Silver D. Heparin-induced thrombocytopenia: pathophysiology and management. Vasc Endovascular Surg 2002;36:163-170 (Pubitemid 35278392)
11. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000;12(Suppl F):27F-32
12. Witting JI, Bourdon P, Brezniak DV, et al. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 1992;283(Pt 3):737-743
13. Robson RA. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000;12:F33-6
14. Maraganore JM, Adelman BA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis 1996;7:438-448 (Pubitemid 26330647)
15. The Medicines company: Angiomax (bivalirudin) package insert. Cambridge, MA 2000
16. Lui HK. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invasive Cardiol 2000;12(Suppl F):41F-452
17. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769
18. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-959 (Pubitemid 33131801)
19. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863 (Pubitemid 37430344)
20. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216 •• Large randomized trial in moderate to high risk patients with NSTEACS comparing bivalirudin with provisional IIb/IIIa antagonists as compared with heparin and IIb/IIIa antagonists. (Pubitemid 44791162)
21. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-919 • 30 day outcomes of ACUITY in patients treated with PCI and bivalirudin provisional IIb/IIIa antagonists as compared with heparin and IIb/IIIa antagonists. (Pubitemid 46400858)
22. Stone GW, Ware JH, Bertrand ME, et al, for the ACUITY Investigators: Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management One-Year Results From the ACUITY Trial. JAMA 2007;298:2497-2506 (Pubitemid 350223536)
23. Mahaffey KW, Yang Q, Pieper KS, et al. Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. J Gen Intern Med 2008;23:310-316
24. White HD, Chew DP, Hoekstra JW, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-STsegment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008;51:1734-1741 (Pubitemid 351621989)
25. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-2230 •• Randomized trial in primary PCI showing reduced mortality with bivalirudin. (Pubitemid 351724451)
26. Stone GW, Witzenbichler MD, Guagliumi G. Comparison of bivalirudin to heparin plus glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in acute myocardial infarction. 12 month outcome of the HORIZONS trial. - 2008
27. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-1562 (Pubitemid 39314961)
28. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-1823 (Pubitemid 37280247)
29. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circ 2006;114:774-782 (Pubitemid 44268228)
30. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-697 (Pubitemid 351221218)
31. Eikelboom JW, Quinlan DJ, Mehta SR, et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circ 2005;112:3855-3867 •• Review of the importance of bleeding in relation to mortality and comparison of different definitions for bleeding. (Pubitemid 43739483)
32. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circ 2007;116:e148-304
33. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-st-segment elevation acute coronary syndromes of the European society of cardiology. Eur Heart J 2007;28:1598-1660 (Pubitemid 47227122)
34. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines Eighth Edition. Chest 2008;133:141S-59S (Pubitemid 351892966)
35. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007;49:1362-1368 • Analysis of the effect of bleeding on outcomes from the ACUITY trial. (Pubitemid 46476844)
36. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130 (Pubitemid 40617065)
37. Escobar GA, Cheng AM, Moore EE, et al. Stored packed red blood cell transfusion up-regulates inflammatory gene expression in circulating leukocytes. Ann Surg 2007;246:129-134 (Pubitemid 47012217)
38. Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circ 2007;116:2544-2552 (Pubitemid 350179219)
39. Kunadian V, Zorkun C, Gibson WJ, et al. Transfusion associated microchimerism: a heretofore little recognized complication following transfusion. J Thromb Thrombolysis 2009;27(1):57-67
40. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 2000;12(Suppl F):14F-9
41. Pinto DS, Stone GW, Shi C, et al. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol 2008;52:1758-1768
42. White HD, Ohman EM, Lincoff AM, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008;52:807-814
43. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989
44. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The thrombolysis in myocardial infarction. Am Heart J 2002;143:229-234
45. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:847-853 (Pubitemid 34595343)
46. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004;93:1092-1096 (Pubitemid 38521035)